LIMMUNOTERAPIA BASED ON IMMUNOLOGICAL CHECKPOINT INHIBITORS REPRESENTS THE EMERGING SECTOR OF CANCER THERAPY, WITH AN EXPONENTIAL GROWTH MARKET. IN PARTICULAR, MONOCLONAL ANTIBODIES (MABS) CAPABLE OF INHIBITING CTLA-4, PD-1 AND PD-L1, APPROVED FOR SE...